Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications

Fenner, F., Henderson, D.A., Arita, I., Jezek, Z., Ladnyi, I.D., and Organization, W.H. (1988). Smallpox and Its Eradication, World Health Organization.

Wehrle, 1980, A reality in our time—Certification of the global eradication of smallpox, J. Infect. Dis., 142, 636, 10.1093/infdis/142.4.636

Henderson, 1999, Smallpox as a biological weapon: Medical and public health management. Working group on civilian biodefense, JAMA, 281, 2127, 10.1001/jama.281.22.2127

Reed, 2004, The detection of monkeypox in humans in the western hemisphere, N. Engl. J. Med., 350, 342, 10.1056/NEJMoa032299

The Centers for Disease Control and Prevention (2003). Multistate outbreak of monkeypox—Illinois, indiana, and wisconsin, 2003. JAMA, 290, 30–31.

Jacobs, 2009, Vaccinia virus vaccines: Past, present and future, Antivir. Res., 84, 1, 10.1016/j.antiviral.2009.06.006

Walsh, 2011, Vaccinia viruses: Vaccines against smallpox and vectors against infectious diseases and tumors, Expert Rev. Vaccines, 10, 1221, 10.1586/erv.11.79

Verardi, 2012, A vaccinia virus renaissance: New vaccine and immunotherapeutic uses after smallpox eradication, Human Vaccines Immunother., 8, 961, 10.4161/hv.21080

Casey, 2005, Adverse events associated with smallpox vaccination in the United States, January–October 2003, JAMA, 294, 2734, 10.1001/jama.294.21.2734

Sejvar, 2005, Neurologic adverse events associated with smallpox vaccination in the united states, 2002–2004, JAMA, 294, 2744, 10.1001/jama.294.21.2744

Murphy, 2005, Adventitious agents and smallpox vaccine in strategic national stockpile, Emerg. Infect. Dis., 11, 1086, 10.3201/eid1107.050277

Weltzin, 2003, Clonal vaccinia virus grown in cell culture as a new smallpox vaccine, Nat. Med., 9, 1125, 10.1038/nm916

Frey, 2009, Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax® in healthy vaccinia-naive adults, Vaccine, 27, 1637, 10.1016/j.vaccine.2008.11.079

Monath, 2004, Acam2000 clonal vero cell culture vaccinia virus (New York city board of health strain)—A second-generation smallpox vaccine for biological defense, Int. J. Infect. Dis., 8, 31, 10.1016/j.ijid.2004.09.002

Greenberg, 2005, Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: A blind, single-centre, randomised controlled trial, Lancet, 365, 398, 10.1016/S0140-6736(05)70234-8

Stittelaar, 2005, Modified vaccinia virus ankara protects macaques against respiratory challenge with monkeypox virus, J. Virol., 79, 7845, 10.1128/JVI.79.12.7845-7851.2005

Stickl, 1974, MVA vaccination against smallpox: Clinical tests with an attenuated live vaccinia virus strain (MVA), Dtsch. Med. Wochenschr., 99, 2386, 10.1055/s-0028-1108143

Mayr, 1978, The smallpox vaccination strain MVA: Marker, genetic structure, experience gained with the parenteral vaccination and behavior in Organisms with a debilitated defence mechanism, Zentralbl. Bakteriol. B, 167, 375

Kitamura, 1967, Immunogenicity of an attenuated strain of vaccinia virus on rabbits and monkeys, Nature, 215, 1187, 10.1038/2151187a0

Hashizume, 1975, Special edition future of smallpox vaccination: Everything about attenuated smallpox vaccines. Basics of new attenuated smallpox vaccine strain LC16m8, Rinshotouirusu, 3, 229

Morita, 1977, Comparative studies of several vaccinia virus strains by intrathalamic inoculation into cynomolgus monkeys, Arch. Virol., 53, 197, 10.1007/BF01314664

Morita, 1977, A comparison of neurovirulence of vaccinia virus by intrathalamic and/or intracisternal inoculations into cynomolgus monkeys, Microbiol. Immunol., 21, 417, 10.1111/j.1348-0421.1977.tb00306.x

Hashizume, S., Yoshizawa, H., Morita, M., and Suzuki, K. (1985). Properties of Attenuated Mutant of Vaccinia Virus, LC16m8, Derived from Lister Strain, Elsevier Science Publishing Co. Inc.

Meyer, 1991, Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence, J. Gen. Virol., 72, 1031, 10.1099/0022-1317-72-5-1031

Wyatt, 1998, Marker rescue of the host range restriction defects of modified vaccinia virus Ankara, Virology, 251, 334, 10.1006/viro.1998.9397

Perkus, 1990, Vaccinia virus host range genes, Virology, 179, 276, 10.1016/0042-6822(90)90296-4

Hanichen, 1975, An attenuated strain of vaccinia virus (MVA). Successful intramuscular immunization against vaccinia and variola, Zentralbl. Bakteriol. Orig. A, 230, 283

Mayr, 2003, Smallpox vaccination and bioterrorism with pox viruses, Comp. Immunol. Microbiol. Infect. Dis., 26, 423, 10.1016/S0147-9571(03)00025-0

Vollmar, 2006, Safety and immunogenicity of imvamune, a promising candidate as a third generation smallpox vaccine, Vaccine, 24, 2065, 10.1016/j.vaccine.2005.11.022

Frey, 2007, Clinical and immunologic responses to multiple doses of imvamune (modified vaccinia Ankara) followed by dryvax challenge, Vaccine, 25, 8562, 10.1016/j.vaccine.2007.10.017

Kennedy, 2009, Imvamune: Modified vaccinia Ankara strain as an attenuated smallpox vaccine, Expert Rev. Vaccines, 8, 13, 10.1586/14760584.8.1.13

Seaman, 2010, Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax, J. Infect. Dis., 201, 1353, 10.1086/651560

Wilck, 2010, Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): Effect of dose and route of administration, J. Infect. Dis., 201, 1361, 10.1086/651561

Kidokoro, 2005, Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8, Proc. Natl. Acad. Sci. USA, 102, 4152, 10.1073/pnas.0406671102

Meseda, 2005, Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine dryvax in a mouse model, Virology, 339, 164, 10.1016/j.virol.2005.06.002

Wyatt, 2004, Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge, Proc. Natl. Acad. Sci. USA, 101, 4590, 10.1073/pnas.0401165101

Ishii, 2002, Structural analysis of vaccinia virus Dis strain: Application as a new replication-deficient viral vector, Virology, 302, 433, 10.1006/viro.2002.1622

Kenner, 2006, LC16m8: An attenuated smallpox vaccine, Vaccine, 24, 7009, 10.1016/j.vaccine.2006.03.087

Kempe, 1968, Smallpox vaccination of eczema patients with a strain of attenuated live vaccinia (CVI-78), Pediatrics, 42, 980, 10.1542/peds.42.6.980

Yamaguchi, 1975, Vaccination research groups research report: Ministry of health and welfare special research: Postvaccination side effects and research regarding treatment of complications, Rinsho Uirusu Clin. Virus, 3, 225

Tartaglia, 1992, NYVAC: A highly attenuated strain of vaccinia virus, Virology, 188, 217, 10.1016/0042-6822(92)90752-B

Paoletti, 1994, Safe and effective poxvirus vectors—NYVAC and ALVAC, Dev. Biol. Stand., 82, 65

Holzer, 1997, Construction of a vaccinia virus deficient in the essential DNA repair enzyme uracil DNA glycosylase by a complementing cell line, J. Virol., 71, 4997, 10.1128/jvi.71.7.4997-5002.1997

Holzer, 1999, Highly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expression, J. Virol., 73, 4536, 10.1128/JVI.73.6.4536-4542.1999

Ober, 2002, Immunogenicity and safety of defective vaccinia virus lister: Comparison with modified vaccinia virus Ankara, J. Virol., 76, 7713, 10.1128/JVI.76.15.7713-7723.2002

Coulibaly, 2005, The nonreplicating smallpox candidate vaccines defective vaccinia lister (DVV-l) and modified vaccinia Ankara (MVA) elicit robust long-term protection, Virology, 341, 91, 10.1016/j.virol.2005.06.043

Najera, 2006, Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene, J. Virol., 80, 6033, 10.1128/JVI.02108-05

Drillien, 2008, Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine, Vaccine, 26, 1794, 10.1016/j.vaccine.2007.12.059

Funahashi, 1991, Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins, Virology, 181, 158, 10.1016/0042-6822(91)90480-Y

Smith, 2002, The formation and function of extracellular enveloped vaccinia virus, J. Gen. Virol., 83, 2915, 10.1099/0022-1317-83-12-2915

Schmelz, 1994, Assembly of vaccinia virus: The second wrapping cisterna is derived from the trans golgi network, J. Virol., 68, 130, 10.1128/jvi.68.1.130-147.1994

Hollinshead, 2001, Vaccinia virus utilizes microtubules for movement to the cell surface, J. Cell Biol., 154, 389, 10.1083/jcb.200104124

Rietdorf, 2001, Kinesin-dependent movement on microtubules precedes actin-based motility of vaccinia virus, Nat. Cell Biol., 3, 992, 10.1038/ncb1101-992

Ward, 2001, Visualization of intracellular movement of vaccinia virus virions containing a green fluorescent protein-B5R membrane protein chimera, J. Virol., 75, 4802, 10.1128/JVI.75.10.4802-4813.2001

Katz, 2003, Mutations in the vaccinia virus A33R and B5R envelope proteins that enhance release of extracellular virions and eliminate formation of actin-containing microvilli without preventing tyrosine phosphorylation of the A36R protein, J. Virol., 77, 12266, 10.1128/JVI.77.22.12266-12275.2003

Newsome, 2004, Src mediates a switch from microtubule- to actin-based motility of vaccinia virus, Science, 306, 124, 10.1126/science.1101509

Payne, 1985, Extracellular release of enveloped vaccinia virus from mouse nasal epithelial cells in vivo, J. Gen. Virol., 66, 643, 10.1099/0022-1317-66-3-643

Galmiche, 1999, Neutralizing and protective antibodies directed against vaccinia virus envelope antigens, Virology, 254, 71, 10.1006/viro.1998.9516

Hooper, 2003, Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates, Virology, 306, 181, 10.1016/S0042-6822(02)00038-7

Pulford, 2004, Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge, Vaccine, 22, 3358, 10.1016/j.vaccine.2004.02.034

Hooper, 2004, Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox, J. Virol., 78, 4433, 10.1128/JVI.78.9.4433-4443.2004

Williamson, 1990, Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route, J. Gen. Virol., 71, 2761, 10.1099/0022-1317-71-11-2761

Kidokoro, M.S.S., Ami, Y., Suzaki, Y., Nagata, N., Iwata, N., Hasegawa, H., Ogata, M., Fukushi, H., Mizutani, T., and Shida, H. (2006, January 19–21). Protective effects of improved smalpox vaccine LC16m8∆ against a lethal monkeypox challenge in cynomolgus monkeys. Proceedings of the 54th Annual Meeting of the Japanese Society for Virology, Nagoya, Japan.

Hooper, 2000, DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge, Virology, 266, 329, 10.1006/viro.1999.0096

Kaufman, 2008, Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice, J. Virol., 82, 6829, 10.1128/JVI.00353-08

Saijo, 2006, LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox, J. Virol., 80, 5179, 10.1128/JVI.02642-05

Morikawa, 2005, An attenuated LC16m8 smallpox vaccine: Analysis of full-genome sequence and induction of immune protection, J. Virol., 79, 11873, 10.1128/JVI.79.18.11873-11891.2005

Benhnia, 2008, Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine, J. Virol., 82, 3751, 10.1128/JVI.02244-07

Townsend, 2013, Humoral immunity to smallpox vaccines and monkeypox virus challenge: Proteomic assessment and clinical correlations, J. Virol., 87, 900, 10.1128/JVI.02089-12

Wollenick, 2009, The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays, Vaccine, 27, 1154, 10.1016/j.vaccine.2008.12.035

Moss, 1991, Vaccinia virus: A tool for research and vaccine development, Science, 252, 1662, 10.1126/science.2047875

Perkus, 1995, Live attenuated vaccinia and other poxviruses as delivery systems: Public health issues, Ann. NY Acad. Sci., 754, 222, 10.1111/j.1749-6632.1995.tb44454.x

Thongcharoen, 2007, A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost, J. Acquir. Immune Defic. Syndr., 46, 48, 10.1097/QAI.0b013e3181354bd7

Casimiro, 2005, Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag, J. Virol., 79, 15547, 10.1128/JVI.79.24.15547-15555.2005

Vogel, 2003, Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239, J. Virol., 77, 13348, 10.1128/JVI.77.24.13348-13360.2003

Cox, 2008, DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles, J. Virol., 82, 8161, 10.1128/JVI.00620-08

Goonetilleke, 2006, Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus ankara-vectored vaccines expressing HIV-1 gag coupled to CD8+ T-cell epitopes, J. Virol., 80, 4717, 10.1128/JVI.80.10.4717-4728.2006

Harari, 2008, An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses, J. Exp. Med., 205, 63, 10.1084/jem.20071331

Tameris, 2013, Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial, Lancet, 381, 1021, 10.1016/S0140-6736(13)60177-4

Walker, 2008, Toward an AIDS vaccine, Science, 320, 760, 10.1126/science.1152622

Kitabatake, 2007, SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus, Vaccine, 25, 630, 10.1016/j.vaccine.2006.08.039

Viner, 2007, B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals, Virology, 361, 356, 10.1016/j.virol.2006.11.020

Jin, 1994, Constructions of vaccinia virus A-type inclusion body protein, tandemly repeated mutant 7.5 kDa protein, and hemagglutinin gene promoters support high levels of expression, Arch. Virol., 138, 315, 10.1007/BF01379134

Kidokoro, 2002, Large-scale preparation of biologically active measles virus haemagglutinin expressed by attenuated vaccinia virus vectors, Microbes Infect., 4, 1035, 10.1016/S1286-4579(02)01627-1

Funahashi, 1988, Cloning and characterization of the gene encoding the major protein of the A-type inclusion body of cowpox virus, J. Gen. Virol., 69, 35, 10.1099/0022-1317-69-1-35

Suzuki, 2009, Immunogenicity of newly constructed attenuated vaccinia strain LC16m8delta that expresses SIV gag protein, Vaccine, 27, 966, 10.1016/j.vaccine.2008.12.015

Kiepiela, 2007, CD8+ T-cell responses to different HIV proteins have discordant associations with viral load, Nat. Med., 13, 46, 10.1038/nm1520

Matano, 2004, Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial, J. Exp. Med., 199, 1709, 10.1084/jem.20040432

Okamura, 2006, Recombinant vaccinia Dis expressing simian immunodeficiency virus gag and pol in mammalian cells induces efficient cellular immunity as a safe immunodeficiency virus vaccine candidate, Microbiol. Immunol., 50, 989, 10.1111/j.1348-0421.2006.tb03867.x

Mackett, 1984, General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes, J. Virol., 49, 857, 10.1128/jvi.49.3.857-864.1984

Hansen, 2009, Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge, Nat. Med., 15, 293, 10.1038/nm.1935

Hansen, 2011, Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine, Nature, 473, 523, 10.1038/nature10003

Sato, 2013, Immunogenicity and safety of the vaccinia virus LC16m8delta vector expressing SIV Gag under a strong or moderate promoter in a recombinant BCG prime-recombinant vaccinia virus boost protocol, Vaccine, 31, 3549, 10.1016/j.vaccine.2013.05.071

Goepfert, 2014, Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles, J. Infect. Dis., 210, 99, 10.1093/infdis/jiu003

Zhang, 2012, Elicitation of both anti HIV-1 Env humoral and cellular immunities by replicating vaccinia prime sendai virus boost regimen and boosting by CD40Lm, PLoS One, 7, e51633, 10.1371/journal.pone.0051633